Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results.
Forty three patients with disseminated malignant melanoma were treated by combination chemotherapy with DTIC (800 mg/m2) and subsequent peroral cyclophosphamide (100 mg/m2) for 14 days. Overall response was observed in 18/43 (42%), and complete response in 9/43 (21%) cases. Complete response was achieved mainly in patients with metastatic involvement of lungs. Mean survival from onset of treatment for responding patients was significantly longer than mean survival of nonresponders (15 versus 5 months, respectively). Serious complications were not noted.
D000328:Adult; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy / Q000556:secondary
D003606:Dacarbazine; D003520:Cyclophosphamide